title: [CUA analysis in new drug evaluation: a review of available tools].
abstract: Cost utility analysis (CUA) is a peculiar kind of efficacy evaluation. The outcome is the quality adjusted years of life derived by comparing an intervention versus a comparator. We review literature analyzing some criticism emerging from Cost Utility evaluation as selection bias or eventual methodological inconsistency. We applied this model to a new drug--Macugen--assessing an incremental cost of 7258.68 euro for a two years treatment schedule. Our analysis suggest that CUA is potential informative especially in certain context as prevention, but efficacy assessment and robust outcomes measuring is crucial.
authors.affiliation: Dipartimento di Scienze Mediche Preventive, Università Federico II, Napoli. fabiana.rubba@unina.it
authors.forename: F
authors.initials: F
authors.lastname: Rubba
authors.forename: S
authors.initials: S
authors.lastname: Panico
authors.forename: P
authors.initials: P
authors.lastname: Cuccaro
authors.forename: Vecchia A
authors.initials: VA
authors.lastname: della
authors.forename: A
authors.initials: A
authors.lastname: Paudice
authors.forename: M
authors.initials: M
authors.lastname: Triassi
mesh_terms: D003362:Cost-Benefit Analysis / Q000379:methods; D004341:Drug Evaluation / Q000191:economics*; D006801:Humans